The safety of diclofenac for the management and treatment of actinic keratoses
| Autor: | Zabiholah Shahmoradi, Amir Hossein Siadat, Shahla Enshaieh, Fariba Iraji, Ali Asilian |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Diclofenac Skin Neoplasms First line Administration Cutaneous Dry skin medicine Humans Pharmacology (medical) Photosensitivity Disorders Hyaluronic Acid business.industry Carcinoma in situ Excessive sun exposure Anti-Inflammatory Agents Non-Steroidal General Medicine Actinic keratoses Keratosis medicine.disease Dermatology Squamous carcinoma Topical medication stomatognathic diseases medicine.symptom business Gels Carcinoma in Situ medicine.drug |
| Zdroj: | Expert opinion on drug safety. 7(2) |
| ISSN: | 1744-764X |
| Popis: | Background: Actinic keratoses (AKs), defined as carcinoma in situ of squamous carcinoma, is usually induced by excessive sun exposure. The efficacy of 3% diclofenac in 2.5% hyaluronic acid gel for treatment of AKs has been documented in a few studies. Objective: Is diclofenac safe and effective for the management and treatment of AKs? Method: All the papers that were cited in Medline and ISI Web of Science are included in this study. Results/conclusion: The use of diclofenac is associated with a few side effects, which include pruritus, rashes, dry skin, and scaling. These side effects are usually minimal and tolerable; therefore, this topical medication is suggested as the first line of treatment for AKs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|